Screener
Ultragenyx Pharmaceutical RARE Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Ultragenyx Pharmaceutical’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333233
FAQ
- What is Ultragenyx Pharmaceutical's total equity?
- Ultragenyx Pharmaceutical (RARE) reported total equity of -$291M in Q2 2026.
- How has Ultragenyx Pharmaceutical's total equity changed year-over-year?
- Ultragenyx Pharmaceutical's total equity decreased by 292.7% year-over-year, from $151M to -$291M.
- What is the long-term trend for Ultragenyx Pharmaceutical's total equity?
- Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's total equity has grown at a -41.4% compound annual growth rate (CAGR), from $1.15B to -$80M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Ultragenyx Pharmaceutical's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude